FORT WORTH, Texas -- (BUSINESS WIRE) --

Galderma, the leading company solely dedicated to advancing the future of dermatology, announced it will be attending the 2022 American Academy of Dermatology Annual Meeting to showcase its latest approved and investigational product updates. This includes clinical data presentations at its product theaters, advisory boards, and booth activities onsite as AAD returns in-person once more.

“We are excited to attend AAD to connect with the dermatology community and showcase our latest innovation and data across our complete dermatology portfolio,” said Baldo Scassellati Sforzolini, Global Head of Research & Development at Galderma. “Our presence underscores our commitment to developing and bringing to market dermatological solutions to address every skin need.”

A considerable amount of new data will be presented during the AAD Congress in the form of abstracts and oral presentations for nemolizumab, a first-in-class investigational monoclonal antibody directed against the interleukin-31 (IL-31) receptor, under clinical development for the treatment of atopic dermatitis and prurigo nodularis.

The data for prurigo nodularis include efficacy data of nemolizumab and its impact on itch and sleep disturbance. An additional seven abstracts look at a variety of aspects of the disease including its prevalence, current treatment practices and the effect of the disease on sleep, mental health disorders and gastrointestinal and hepatobiliary diseases. Three abstracts in atopic dermatitis look at the safety and efficacy of nemolizumab in adolescents and the impact of nemolizumab according to EASI and Scorad components.

Galderma will present thirteen study abstracts regarding its investigational monoclonal antibody that targets the IL-31 receptor, nemolizumab. Data comes from Phase 2 studies and real-world evidence. More details on Galderma’s activities can be found below.